CPC A61K 9/0021 (2013.01) [A61B 5/150984 (2013.01); A61K 39/39 (2013.01); A61K 47/58 (2017.08); A61K 2039/505 (2013.01)] | 7 Claims |
1. A method of vaccinating a patient for SARS-CoV-2, comprising administering to the patient an amount of a composition, by a route of administration effective to induce an immune response to SARS-CoV-2, wherein said composition comprises (a) a fusion polypeptide comprising (i) an immunogenic amino acid sequence of a SARS-CoV-2 spike protein and (ii) a Toll-like receptor agonist domain, and (b) a pharmaceutically acceptable excipient, wherein said Toll-like receptor agonist domain is a polypeptide.
|